Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series

Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasad, Femin, De, Riddhita, Korann, Vittal, Chintoh, Araba F., Remington, Gary, Ebdrup, Bjørn H., Siskind, Dan, Knop, Filip Krag, Vilsbøll, Tina, Fink-Jensen, Anders, Hahn, Margaret K., Agarwal, Sri Mahavir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126648/
https://www.ncbi.nlm.nih.gov/pubmed/37113745
http://dx.doi.org/10.1177/20451253231165169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126648/
https://www.ncbi.nlm.nih.gov/pubmed/37113745
http://dx.doi.org/10.1177/20451253231165169

Ejemplares similares